June 2026

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This is an encore presentation from the 2025 American Pharmacists Association Annual Meeting and Exposition in Nashville, Tennessee. This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

A candid midlife reckoning in modern pharmacy care: Reclaim purpose, question the system, and reconnect work to meaning, patient impact, and wholehearted living.

FDA clears teclistamab plus daratumumab after first relapse, delivering striking PFS gains—plus practical tips to manage CRS, ICANS, and infections.

Specialty pharmacy technicians address barriers in oral anticancer therapy and transitions of care through improved care coordination and therapy access.

Inlexzo Gemcitabine Intravesical System delivers sustained therapy for BCG-unresponsive NMIBC, raising complete response and avoiding cystectomy.

Real‑world study finds grade 1 CRS during CD20 bispecific therapy for follicular lymphoma is often safe at home, reducing hospital use.

Mayo Clinic tackles medication shortages with batching and fair overtime, keeping oncology acetaminophen available in a Pharmacy Times peer review.

MRD monitoring detects microscopic disease levels to guide treatment decisions, providing actionable insights for pharmacists.

A reflection from HOPA 2026 explores medical misinformation and how oncology pharmacists can strengthen trust and guide evidence-based patient care.

Skin Cancer Awareness Month in May spotlights oncology pharmacists driving prevention, innovative care, and supply-chain resilience built on patient trust.

Pharmacist lung cancer insights on NSCLC: biomarker testing, PD-1 choices like cemiplimab, and access tips for treating non small cell lung cancer.